Taietti I, Catamero F, Lodi L, Giovannini M, Castagnoli R
Curr Opin Allergy Clin Immunol. 2025; 25(2):105-114.
PMID: 39945219
PMC: 11872271.
DOI: 10.1097/ACI.0000000000001059.
Lutzu N, Favale A, Demurtas M, Del Giacco S, Onali S, Fantini M
Front Med (Lausanne). 2025; 11:1513417.
PMID: 39906352
PMC: 11790572.
DOI: 10.3389/fmed.2024.1513417.
Fasshauer M, Dinges S, Staudacher O, Voller M, Stittrich A, von Bernuth H
Front Pediatr. 2024; 12:1386959.
PMID: 38933494
PMC: 11203071.
DOI: 10.3389/fped.2024.1386959.
Diaz-Cabrera N, Bauman B, Iro M, Dabbah-Krancher G, Molho-Pessach V, Zlotogorski A
J Clin Immunol. 2024; 44(2):48.
PMID: 38231347
DOI: 10.1007/s10875-023-01636-y.
Brailean A, Kwiatek J, Kielar D, Katial R, Wang X, Xu X
Allergy Asthma Immunol Res. 2023; 15(5):580-602.
PMID: 37827978
PMC: 10570778.
DOI: 10.4168/aair.2023.15.5.580.
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H, Sadik C, Ludwig R, Thaci D, Boch K
Biomolecules. 2023; 13(4).
PMID: 37189381
PMC: 10136243.
DOI: 10.3390/biom13040634.
Food Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants.
Guarnieri K, Saba N, Schwartz J, Devonshire A, Bufford J, Casale T
J Allergy Clin Immunol Pract. 2023; 11(5):1509-1521.e6.
PMID: 36801492
PMC: 10164686.
DOI: 10.1016/j.jaip.2023.02.008.
Eosinophilic Gastrointestinal Diseases in Inborn Errors of Immunity.
Votto M, Naso M, Brambilla I, Caimmi S, De Filippo M, Licari A
J Clin Med. 2023; 12(2).
PMID: 36675441
PMC: 9867405.
DOI: 10.3390/jcm12020514.
Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience.
Shamriz O, Rubin L, Simon A, Lev A, Barel O, Somech R
Front Immunol. 2023; 13:1044933.
PMID: 36605204
PMC: 9807906.
DOI: 10.3389/fimmu.2022.1044933.
Eosinophilic gastrointestinal disorders in patients with inborn errors of immunity: Data from the USIDNET registry.
Tran P, Gober L, Garabedian E, Fuleihan R, Puck J, Sullivan K
Front Immunol. 2022; 13:987895.
PMID: 36211419
PMC: 9539548.
DOI: 10.3389/fimmu.2022.987895.
Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.
Joshi T, Wang H, Athukuri P, Bohac S, Farr M, Hinson D
Am J Clin Dermatol. 2022; 23(5):673-688.
PMID: 35606649
DOI: 10.1007/s40257-022-00700-4.
Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.
Lan J, Zhang Y, Song M, Cai S, Luo H, Ouyang R
Front Med (Lausanne). 2022; 9:835257.
PMID: 35602476
PMC: 9114644.
DOI: 10.3389/fmed.2022.835257.
Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.
Matucci-Cerinic C, Viglizzo G, Pastorino C, Corcione A, Prigione I, Bocca P
Pediatr Allergy Immunol. 2022; 33(4):e13770.
PMID: 35470938
PMC: 9321118.
DOI: 10.1111/pai.13770.
Targeted IL-4Rα blockade ameliorates refractory allergic eosinophilic inflammation in a patient with dysregulated TGF-β signaling due to ERBIN deficiency.
Droghini H, Abonia J, Collins M, Milner J, Lyons J, Freeman A
J Allergy Clin Immunol Pract. 2022; 10(7):1903-1906.
PMID: 35093604
PMC: 9271541.
DOI: 10.1016/j.jaip.2022.01.012.
